<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Hematology Am Soc Hematol Educ Program</journal-id>
<journal-id journal-id-type="iso-abbrev">Hematology Am Soc Hematol Educ Program</journal-id>
<journal-id journal-id-type="hwp">bloodbook</journal-id>
<journal-id journal-id-type="publisher-id">bloodbook</journal-id>
<journal-title-group>
<journal-title>Hematology: the American Society of Hematology Education Program</journal-title>
</journal-title-group>
<issn pub-type="ppub">1520-4391</issn>
<issn pub-type="epub">1520-4383</issn>
<publisher>
<publisher-name>American Society of Hematology</publisher-name>
<publisher-loc>Washington, DC</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29222263</article-id>
<article-id pub-id-type="pmc">6142611</article-id>
<article-id pub-id-type="publisher-id">00034</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Dilemmas in Pediatric Hematologic Malignancy</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Crisis management in the treatment of childhood acute lymphoblastic leukemia: putting right what can go wrong (emergency complications of disease and treatment)</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Hough</surname>
<given-names>Rachael</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Vora</surname>
<given-names>Ajay</given-names>
</name>
<xref ref-type="aff" rid="aff2">2</xref>
</contrib>
<aff id="aff1"><label>1</label>Department of Adolescent Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom; and </aff>
<aff id="aff2"><label>2</label>Department of Haematology, Great Ormond Street Hospital for Children, London, United Kingdom</aff>
</contrib-group>
<author-notes>
<corresp id="cor1"><bold>Correspondence</bold> Rachael Hough, Department of Haematology, University College London Hospital’s National Health Service Foundation Trust, 250 Euston Rd, London NW1 2PG, United Kingdom; e-mail: <email>rachael.hough@uclh.nhs.uk</email>.</corresp>
<fn fn-type="COI-statement">
<p>Conflict-of-interest disclosure: The authors declare no competing financial interests.</p>
</fn>
<fn fn-type="other">
<p>Off-label drug use: None disclosed.</p>
</fn>
</author-notes>
<pub-date pub-type="ppub">
<day>8</day>
<month>12</month>
<year>2017</year>
</pub-date>
<volume>2017</volume>
<issue>1</issue>
<fpage>251</fpage>
<lpage>258</lpage>
<permissions>
<copyright-statement>© 2016 by The American Society of Hematology. All rights reserved.</copyright-statement>
<copyright-year>2017</copyright-year>
<copyright-holder>American Society of Hematology</copyright-holder>
</permissions>
<self-uri xlink:href="bloodbook-2017-251.pdf" xlink:title="pdf"></self-uri>
<abstract>
<p>The improvement in overall survival in children with acute lymphoblastic leukemia (ALL) over the last 5 decades has been considerable, with around 90% now surviving long term. The risk of relapse has been reduced to such an extent that the risk of treatment-related mortality is now approaching that of mortality caused by relapse. Toxicities may also lead to the suboptimal delivery of chemotherapy (treatment delays, dose reductions, dose omissions), potentially increasing relapse risk, and short- and long-term morbidity, adding to the “burden of therapy” in an increasing number of survivors. Thus, the need to reduce toxicity in pediatric ALL is becoming increasingly important. This work focuses on the risk factors, pathogenesis, clinical features, and emergency management of the life-threatening complications of ALL at presentation and during subsequent chemotherapy, including leucostasis, tumor lysis syndrome, infection, methotrexate encephalopathy, thrombosis, and pancreatitis. Potential strategies to abrogate these toxicities in the future are also discussed.</p>
</abstract>
<counts>
<page-count count="8"></page-count>
</counts>
</article-meta>
</front>
</article>
</pmc-articleset>